Compare PICS & TRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PICS | TRAX |
|---|---|---|
| Founded | 2012 | 2025 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2021 | 2026 |
| Metric | PICS | TRAX |
|---|---|---|
| Price | $13.69 | $31.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | $19.61 | ★ $70.58 |
| AVG Volume (30 Days) | 490.5K | ★ 604.3K |
| Earning Date | 08-24-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $48.94 | N/A |
| Revenue Next Year | $38.31 | N/A |
| P/E Ratio | $29.44 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.11 | $15.69 |
| 52 Week High | $18.49 | $49.91 |
| Indicator | PICS | TRAX |
|---|---|---|
| Relative Strength Index (RSI) | 72.20 | 35.27 |
| Support Level | $13.20 | $15.69 |
| Resistance Level | $13.78 | $48.94 |
| Average True Range (ATR) | 0.75 | 2.55 |
| MACD | 0.55 | -0.43 |
| Stochastic Oscillator | 98.32 | 9.46 |
PicS NV is a digital payments company. The company operates a peer-to-peer (P2P) transfer platform that enables individuals to send money via mobile devices. It provides digital wallets, instant payments (Pix), P2P transfers, credit cards, loans, investments, insurance, and SMB payment solutions. The company has four reportable segments: Consumer Banking, Small and Medium-Sized Businesses, Audiences and Ecosystem Integration, and Institutional. The majority of the company's revenue is derived from the Consumer Banking segment, which generates revenue from various transaction activities occurring in the digital wallet, such as Pix, peer-to-peer (P2P) transfers, and bill payments.
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.